NAMPT and neoplasm: Low-dose clinical NAMPT inhibitor OT-82 depletes NAD+ and inhibits cell growth through a metabolic defect characterized by significant impairment of glycolysis and diminished oxidative phosphorylation, leading to profound ATP depletion, irreversible necrotic cell death, and complete tumor regression when administered according to the clinical schedule in rhabdomyosarcoma [123].